CoChat

Structural basis for selective inhibition of human GABA transporter GAT3

Open access

Preprint — published as 10.1038/s41467-026-68479-0 · Paper page

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

The astrocytic γ-aminobutyric acid (GABA) transporter, GAT3, is essential for terminating GABAergic signalling in the central nervous system. Selective inhibition of GAT3 offers a potential strategy for elevating extracellular GABA levels for the treatment of neurological disorders including epilepsy. However, few potent and selective GAT3 inhibitors have been developed, and their mechanisms of inhibition remain poorly understood. Here, we present the cryo-electron microscopy structures of full-length, wild-type human GAT3 bound to a selective inhibitor, to substrate GABA, or in substrate-free state. GAT3 bound to the inhibitor or in the substrate-free state exhibits an inward-open conformation. The inhibitor binds within the intracellular permeation pathway, positioned between transmembrane helices 1, 2, 3, 6, 7, and 8. The GABA-bound GAT3 is captured in an inward-occluded state, revealing the ion coordination and substrate recognition network, including a cation-π interaction between GABA’s γ-amino group and a phenylalanine residue in transmembrane helix 6. Our data reveal the molecular determinants for the inhibitor selectivity, and the mode of substrate binding and transport inhibition, providing blueprints for the rational design of next-generation selective GAT3 inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2025.03.27.645797

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 SR-THAP is a selective non-competitive inhibitor of hGAT3. a SR-THAP inhibits [3H]GABA uptake by hGAT3 expressed in HEK293T cells with an IC50 of 25.2 [21.8; 30.4] μM without preincubation (blue) and 4.4 [3.6; 5.2] µM, 4.5 [3.4; 5.9] µM, and 4.9 [3.3; 7.0] μM after 15, 30, and 120 min preincubation, respectively. b The enantiomer RS-THAP inhibits [3H]GABA uptake by hGAT3 expressed in HEK293T cells, but with significantly reduced potency, with estimated IC50 values of >600 μM without preincubation and >100 μM with preincubation. c [3H]GABA uptake by hGAT3 can also be inhibited by non-radioactive GABA, although showing minimal shift in potency after 120 min preincubation, with IC50 values of 8.5 [6.4; 11] and 5.4 [4.6; 6.4] μM, respectively. d [3H]GABA uptake kinetic experiment fitted to the Michaelis–Menten model, performed with increasing concentrations of SR-THAP without preincubation (left) or after 120 min of preincubation (middle), before addition of [3H]GABA. Right panel shows the Michaelis–Menten kinetic parameters derived from the graphs in the left and middle panels, without (top) and with (bottom) 120 min preincubation. Statistical differences from control were determined by a two-sided F test and are indicated with stars as: * - P ≤ 0.05, ** - P ≤ 0.01. For reference, the F-test p values were 0.029 (0.5 µM), 0.0021 (2 µM), and 0.0015 (10 µM) without preincubation, and 0.652 (0.5 µM) and 0.0022 (2 µM) with preincubation. Data points are shown as individual replicates from n = 3 biological replicates (triplicate measurements) unless otherwise stated. Source data are provided as a Source data file.
Fig. 1 SR-THAP is a selective non-competitive inhibitor of hGAT3. a SR-THAP inhibits [3H]GABA uptake by hGAT3 expressed in HEK293T cells with an IC50 of 25.2 [21.8; 30.4] μM without preincubation (blue) and 4.4 [3.6; 5.2] µM, 4.5 [3.4; 5.9] µM, and 4.9 [3.3; 7.0] μM after 15, 30, and 120 min preincubation, respectively. b The enantiomer RS-THAP inhibits [3H]GABA uptake by hGAT3 expressed in HEK293T cells, but with significantly reduced potency, with estimated IC50 values of >600 μM without preincubation and >100 μM with preincubation. c [3H]GABA uptake by hGAT3 can also be inhibited by non-radioactive GABA, although showing minimal shift in potency after 120 min preincubation, with IC50 values of 8.5 [6.4; 11] and 5.4 [4.6; 6.4] μM, respectively. d [3H]GABA uptake kinetic experiment fitted to the Michaelis–Menten model, performed with increasing concentrations of SR-THAP without preincubation (left) or after 120 min of preincubation (middle), before addition of [3H]GABA. Right panel shows the Michaelis–Menten kinetic parameters derived from the graphs in the left and middle panels, without (top) and with (bottom) 120 min preincubation. Statistical differences from control were determined by a two-sided F test and are indicated with stars as: * - P ≤ 0.05, ** - P ≤ 0.01. For reference, the F-test p values were 0.029 (0.5 µM), 0.0021 (2 µM), and 0.0015 (10 µM) without preincubation, and 0.652 (0.5 µM) and 0.0022 (2 µM) with preincubation. Data points are shown as individual replicates from n = 3 biological replicates (triplicate measurements) unless otherwise stated. Source data are provided as a Source data file.CC BY-NC-ND · PubMed Central
Fig. 2 Inhibitor-bound and GABA-bound states of hGAT3. Cryo-EM density maps of hGAT3 bound to a SR-THAP (blue map, contour level = 0.063 in ChimeraX), and b GABA (green map, contour level = 0.06 in ChimeraX). Lipid densities are shown in light yellow. c, d Surface representation of the inhibitor-bound and GABA-bound structures of hGAT3 viewed parallel to the membrane. c Slice view of hGAT3 showing the SR-THAP (orange) binding pocket. d Slice view of hGAT3 showing the GABA (green) binding pocket. The extracellular gating residues R75 (TM1 – blue) and D467 (TM10 – not shown), as well as P375 (EL4 – yellow) and F308 (TM6 – green), are shown as sticks in c, d.
Fig. 2 Inhibitor-bound and GABA-bound states of hGAT3. Cryo-EM density maps of hGAT3 bound to a SR-THAP (blue map, contour level = 0.063 in ChimeraX), and b GABA (green map, contour level = 0.06 in ChimeraX). Lipid densities are shown in light yellow. c, d Surface representation of the inhibitor-bound and GABA-bound structures of hGAT3 viewed parallel to the membrane. c Slice view of hGAT3 showing the SR-THAP (orange) binding pocket. d Slice view of hGAT3 showing the GABA (green) binding pocket. The extracellular gating residues R75 (TM1 – blue) and D467 (TM10 – not shown), as well as P375 (EL4 – yellow) and F308 (TM6 – green), are shown as sticks in c, d.CC BY-NC-ND · PubMed Central
Fig. 3 Inhibitor SR-THAP and substrate GABA bind to the central binding pocket of hGAT3. a Overall structure of the human GAT3 bound to the selective inhibitor SR-THAP (orange sticks) and cryo-EM density of SR-THAP (map contour level = 0.072 in ChimeraX). b Zoomed-in view of the binding mode of SR-THAP (orange) of hGAT3. Protein backbone is shown as ribbons (azure) and chloride ion as green sphere. Interacting residues within 3 Å of the inhibitor are displayed. To better illustrate the compound’s protonation state and its interactions with hGAT3, the polar hydrogens are shown even though they are not resolved at this resolution. H-bonds and cation-π interactions are displayed with yellow and green dashed lines, respectively. c The hGAT3-E66Y mutant shows a near-complete loss of [3H]GABA uptake, with only ~5% transport activity remaining compared to wild-type hGAT3, while hGAT3-C316S retains approximately 60% transport activity. Data points are individual measurements from either two biological replicates (hGAT3-E66Y) or three biological replicates (hGAT3-wt and hGAT3-C316S), each biological replicate was measured in triplicates. Error bars for hGAT3-wt and hGAT3-C316S represent SEM, and for hGAT3-E66Y, they represent SD. d [3H]GABA uptake inhibition by non-radioactive GABA is not affected in the hGAT3-C316S mutant compared to the wild-type hGAT3 with an IC50 value of 4.2 [2.3; 7.9] μM. e [3H]GABA inhibition by SR-THAP is affected by the C316S mutation with a reduced potency of 10.6 [8.6; 12.7] μM, compared to 4.9 [3.3; 7.0] μM for the wild-type hGAT3. Both experiments were performed with 120 min preincubation. Data points are shown as individual replicates from n = 3 biological replicates (triplicate measurements) unless otherwise stated. f Overall structure of the hGAT3 bound to its substrate GABA (blue sticks) and cryo-EM density map of GABA (map contour level = 0.06 in ChimeraX). g Zoomed-in view of the binding mode of GABA (blue) at hGAT3. Protein backbone is shown as ribbons (green), chloride ion as a green sphere, sodium ion as a red sphere, and the same residues from (b) as sticks. Source data are provided as a Source data file.
Fig. 3 Inhibitor SR-THAP and substrate GABA bind to the central binding pocket of hGAT3. a Overall structure of the human GAT3 bound to the selective inhibitor SR-THAP (orange sticks) and cryo-EM density of SR-THAP (map contour level = 0.072 in ChimeraX). b Zoomed-in view of the binding mode of SR-THAP (orange) of hGAT3. Protein backbone is shown as ribbons (azure) and chloride ion as green sphere. Interacting residues within 3 Å of the inhibitor are displayed. To better illustrate the compound’s protonation state and its interactions with hGAT3, the polar hydrogens are shown even though they are not resolved at this resolution. H-bonds and cation-π interactions are displayed with yellow and green dashed lines, respectively. c The hGAT3-E66Y mutant shows a near-complete loss of [3H]GABA uptake, with only ~5% transport activity remaining compared to wild-type hGAT3, while hGAT3-C316S retains approximately 60% transport activity. Data points are individual measurements from either two biological replicates (hGAT3-E66Y) or three biological replicates (hGAT3-wt and hGAT3-C316S), each biological replicate was measured in triplicates. Error bars for hGAT3-wt and hGAT3-C316S represent SEM, and for hGAT3-E66Y, they represent SD. d [3H]GABA uptake inhibition by non-radioactive GABA is not affected in the hGAT3-C316S mutant compared to the wild-type hGAT3 with an IC50 value of 4.2 [2.3; 7.9] μM. e [3H]GABA inhibition by SR-THAP is affected by the C316S mutation with a reduced potency of 10.6 [8.6; 12.7] μM, compared to 4.9 [3.3; 7.0] μM for the wild-type hGAT3. Both experiments were performed with 120 min preincubation. Data points are shown as individual replicates from n = 3 biological replicates (triplicate measurements) unless otherwise stated. f Overall structure of the hGAT3 bound to its substrate GABA (blue sticks) and cryo-EM density map of GABA (map contour level = 0.06 in ChimeraX). g Zoomed-in view of the binding mode of GABA (blue) at hGAT3. Protein backbone is shown as ribbons (green), chloride ion as a green sphere, sodium ion as a red sphere, and the same residues from (b) as sticks. Source data are provided as a Source data file.CC BY-NC-ND · PubMed Central
Fig. 4 Schematic illustration of the inward facing states of hGAT3 in the transport cycle. Occlusion of the extracellular pathway is maintained by a highly conserved interaction network, including a salt bridge between R75 and D467 (not shown) and stacking and cation-π interaction of R75 and F308. From the occluded GABA-bound state, the transporter transitions to an inward-open state, by an outward tilt of TM1a as well as partial unwinding of the intracellular part of TM5. The hGAT3 selective inhibitor SR-THAP, after diffusion across the plasma membrane, binds hGAT3, locking the transporter in an inward-open conformation. The residue E66 in the binding pocket of hGAT3, which is replaced by a bulky aromatic tyrosine in hGAT1, may contribute to the selectivity of SR-THAP for hGAT3 over hGAT1. Cl– and Na+ ions are shown as yellow and purple spheres.
Fig. 4 Schematic illustration of the inward facing states of hGAT3 in the transport cycle. Occlusion of the extracellular pathway is maintained by a highly conserved interaction network, including a salt bridge between R75 and D467 (not shown) and stacking and cation-π interaction of R75 and F308. From the occluded GABA-bound state, the transporter transitions to an inward-open state, by an outward tilt of TM1a as well as partial unwinding of the intracellular part of TM5. The hGAT3 selective inhibitor SR-THAP, after diffusion across the plasma membrane, binds hGAT3, locking the transporter in an inward-open conformation. The residue E66 in the binding pocket of hGAT3, which is replaced by a bulky aromatic tyrosine in hGAT1, may contribute to the selectivity of SR-THAP for hGAT3 over hGAT1. Cl– and Na+ ions are shown as yellow and purple spheres.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 69

  1. 10.1124/pr.108.000869 · DOI · Paper page
  2. 10.1016/0197-0186(95)00158-1 · DOI · Paper page
  3. 10.1016/j.brainresrev.2004.03.003 · DOI · Paper page
  4. 10.3389/fendo.2013.00165 · DOI · Paper page
  5. 10.1073/pnas.0809513106 · DOI · Paper page
  6. 10.1038/ncomms13572 · DOI · Paper page
  7. 10.1124/jpet.102.034819 · DOI
  8. 10.1126/scitranslmed.abj4310 · DOI
  9. 10.1177/0271678X17744123 · DOI
  10. 10.1038/nature09511 · DOI · Paper page
  11. 10.1038/ncomms5159 · DOI · Paper page
  12. 10.2165/00003495-199855030-00013 · DOI
  13. 10.1038/nrn1625 · DOI · Paper page
  14. 10.1113/jphysiol.2012.246298 · DOI · Paper page
  15. 10.1007/978-3-319-55769-4_7 · DOI
  16. 10.1002/cmdc.201200126 · DOI
  17. 10.1007/s00044-023-03126-7 · DOI
  18. 10.1038/211969a0 · DOI · Paper page
  19. 10.1038/nature17629 · DOI · Paper page
  20. 10.1038/nature12533 · DOI · Paper page
  21. 10.1038/s41586-024-07804-3 · DOI
  22. 10.1016/j.cell.2023.04.010 · DOI
  23. 10.1038/s41586-022-04814-x · DOI · Paper page
  24. 10.1038/s41586-021-03274-z · DOI · Paper page
  25. 10.1111/jnc.16179 · DOI
  26. 10.1038/s41586-024-07638-z · DOI
  27. 10.1038/s41586-024-07796-0 · DOI
  28. 10.1038/s41594-023-01011-w · DOI
  29. 10.1186/1741-7007-10-26 · DOI · Paper page
  30. 10.1016/j.bcp.2013.06.007 · DOI
  31. 10.1016/j.bmcl.2008.09.005 · DOI
  32. 10.1038/nature03978 · DOI · Paper page
  33. 10.1016/j.neuropharm.2019.05.021 · DOI
  34. 10.1074/jbc.M117.775189 · DOI
  35. 10.1038/s41594-023-00983-z · DOI
  36. 10.1038/s41467-020-14735-w · DOI
  37. 10.1038/nsmb.2894 · DOI · Paper page
  38. 10.1038/s41586-024-07719-z · DOI
  39. Zhu, A. H. , Junhao; Kong, Fang ; Tan, Jiaxin ; Lei, Jianlin ; Yuan, Yafei ; Yan, Chuangye . Molecular basis for substrate recognition and transport of human GABA transporter GAT1. Nature Structural & Molecular Biology (2023). · DOI
  40. 10.1038/s41586-019-1135-1 · DOI · Paper page
  41. 10.1074/jbc.M210525200 · DOI
  42. 10.1074/jbc.M111.323634 · DOI
  43. 10.1074/jbc.M110.149732 · DOI
  44. 10.15252/embj.2020105164 · DOI
  45. 10.15252/embj.2020105164 · DOI
  46. 10.1016/0014-5793(95)00859-8 · DOI
  47. 10.1016/j.cell.2024.02.026 · DOI
  48. 10.1038/ncomms11673 · DOI
  49. 10.1038/s41594-023-01032-5 · DOI
  50. 10.1126/sciadv.abl3857 · DOI · Paper page
  51. 10.1038/nature14431 · DOI · Paper page
  52. 10.1002/glia.24585 · DOI · Paper page
  53. 10.1042/ebc20220208 · DOI
  54. 10.1111/j.1471-4159.1977.tb10721.x · DOI · Paper page
  55. 10.1016/S0028-3908(00)00075-7 · DOI
  56. 10.1177/0271678x17743669 · DOI
  57. 10.1016/j.ejmech.2013.04.063 · DOI
  58. 10.1016/j.bmc.2018.05.049 · DOI
  59. 10.2174/138620709787581684 · DOI
  60. 10.1038/nmeth.4169 · DOI · Paper page
  61. 10.1107/S205225252000929X · DOI
  62. 10.1038/s41592-020-00990-8 · DOI · Paper page
  63. 10.1002/pro.3943 · DOI · Paper page
  64. 10.1107/S2052252519007619 · DOI · Paper page
  65. 2019, Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix, Acta Cryst, D75, 861
  66. 10.1107/S0907444910007493 · DOI · Paper page
  67. 10.1107/S2059798318002425 · DOI · Paper page
  68. 10.1007/s10822-013-9644-8 · DOI · Paper page
  69. 10.1021/jm051256o · DOI · Paper page

Metadata

Authors
Mortensen, J. S., Bavo, F., Smiszek Pedersen, A. P., Storm, J. P., Pape, T., Frølund, B., Wellendorph, P., & Shahsavar, A.
Affiliations
  • University of Copenhagen (DK)
  • Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
Corresponding author
  • Wellendorph, Petrine
  • Shahsavar, Azadeh
Venue
Nature Communications
Publisher
openRxiv
Published
2025-03-28
Volume
17
Issue
1
Pages
1774-1774
ISSN
2041-1723 (ISSN-L)
OpenAlex
W7126066672
Cited by
4
References
1
Citations by year
2026: 3 · 2025: 1
FWCI
7.28
Type
journal article
Language
en
Open access
Locations
  • Nature Communications (publishedVersion, cc-by-nc-nd)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Lundbeckfonden (R368-2021-522)
  • Novo Nordisk
  • Novo Nordisk Fonden (NFF20OC0065017, NNF24SA0098829, NNF21OC0067835)
  • H. Lundbeck A/S
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
Keywords
GAT-3, GABA transporters, GABAergic neurotransmission, transporter inhibition, inhibitor selectivity, cryo-EM structure, GABA binding, substrate recognition, cation-π interactions, inward-open conformation, epilepsy, rational drug design
MeSH terms
gamma-Aminobutyric Acid, Humans, Models, Molecular, Nipecotic Acids, Protein Binding, Protein Conformation, Cryoelectron Microscopy, GABA Plasma Membrane Transport Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Structural basis for selective inhibition of human GABA transporter GAT3. https://app.cochat.ai/papers/10.1101/2025.03.27.645797
The paper
Mortensen, J. S., Bavo, F., Smiszek Pedersen, A. P., Storm, J. P., Pape, T., Frølund, B., Wellendorph, P., & Shahsavar, A. (2025). Structural basis for selective inhibition of human GABA transporter GAT3. Nature Communications. https://doi.org/10.1101/2025.03.27.645797

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.